Significant efforts are being made worldwide to understand the immune response to SARS-CoV-2, responsible for the COVID-19 pandemic, including the role of pre-existing T cell immunity. Understanding the mechanisms that promote cross-recognition by T cells induced by seasonal coronaviruses will be critical for future predictions on the role of pre-existing immunity in protection against severe disease. We demonstrate that the SARS-CoV-2 nucleocapsid (N) protein induces an immunodominant response in HLA-B7+ COVID-19-recovered individuals that is also readily detectable in unexposed donors. This immunodominant response is driven by a single N-encoded epitope that displays a high degree of conservation with the homologous region in circulating coronaviruses. We show that T cell-mediated cross-reactivity can be detected towards the circulating OC43/HKU-1 coronaviruses, but not the 229E or NL63 coronaviruses, due to different peptide conformations. This cross-reactivity is driven by private T cell receptor repertoires with a bias for TRBV27 and a long CDR3b loop in unexposed and COVID-19-recovered individuals. Together, our findings demonstrate the basis of pre-existing immunity to a conserved and highly immunogenic SARS-CoV-2 epitope driven by cross-reactive memory T cells, suggesting long-lived protective immunity.
Funding: This work was supported by generous donations from the QIMR Berghofer COVID 19 appeal, and financial contributions from Monash University, Australian Nuclear Science and Technology Organisation (ANSTO, AISNE ECR grants), Australian Research Council (ARC), National Health and Medical Research Council (NHMRC), and the Medical Research Future Fund (MRFF). H.S. is supported by an Australian Government Research Training Program Scholarship, E.J.G. was supported by an NHMRC CJ Martin Fellowship (#1110429) and is supported by an Australian Research Council DECRA (DE210101479), K.R.S.is supported by an Australian Research Council DECRA (DE180100512), S.G. is supported by and NHMRC SRF (#1159272).
Conflict of Interest: The authors declare no competing interests.
Ethical Approval: This study was performed according to the principles of the Declaration of Helsinki.Ethics approval to undertake the research was obtained from the QIMR Berghofer Medical Research Institute Human Research Ethics Committee and Monash University Human Research Ethics Committee.
Lineburg, Katie E. and Grant, Emma J. and Swaminathan, Srividhya and Chatzileontiadou, Demetra S.M. and Szeto, Christopher and Sloane, Hannah and Panikkar, Archana and Raju, Jyothy and Crooks, Pauline and Rehan, Sweera and Nguyen, Andrea and Lekieffre, Lea and Neller, Michelle A. and Tong, Zhen Wei Marcus and Jayasinghe, Dhilshan and Chew, Keng Yih and Lobos, Christian A. and Halim, Hanim and Burrows, Jacqueline M. and Riboldi-Tunnicliffe, Alan and Chen, Weisan and D'Orsogna, Lloyd and Khanna, Rajiv and Short, Kirsty R. and Smith, Corey and Gras, Stephanie, Pre-Existing Cellular Immunity to SARS-CoV-2 Through an Immunodominant Epitope. Available at SSRN: https://ssrn.com/abstract=3774361 or http://dx.doi.org/10.2139/ssrn.3774361
This version of the paper has not been formally peer reviewed.
Subscribe to this free journal for more curated articles on this topic
FOLLOWERS
16
PAPERS
8,007
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.